Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 739

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Open access
Horwitz, Steven, O'Connor, Owen A, Pro, Barbara, Illidge, Tim, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J, Yuen, Sam, Iyer, Swaminathan, Zinzani, Pier Luigi, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Trümper, Lorenz, Aboulafia, David, Advani, Ranjana, Alpdogan, Onder, Ando, Kiyoshi, Arcaini, Luca, Baldini, Luca, Bellam, Naresh, Bartlett, Nancy, Belada, David, Yehuda, Dina Ben, Benedetti, Fabio, Borchman, Peter, Bordessoule, Dominique, Brice, Pauline, Briones, Javier, Caballero, Dolores, Carella, Angelo Michele, Chang, Hung, Cheong, June Weon, Cho, Seok-Goo, Choi, Ilseung, Choquet, Sylvain, Colita, Andrei, Congui, Angela Giovanna, D'amore, Francesco, Dang, Nam, Davison, Kelly, de Guibert, Sophie, Brown, Peter de Nully, Delwail, Vincent, Demeter, Judit, di Raimondo, Francesco, Do, Young Rok, Domingo, Eva, Douvas, Michael, Dreyling, Martin, Ernst, Thomas, Fanale, Michelle, Fay, Keith, Feldman, Tatyana, Ferrero, Silvia Fernandez, Flinn, Ian Winchester, Forero-Torres, Andres, Fox, Christopher, Friedberg, Jonathan, Fukuhara, Noriko, Garcia-Marco, Jose, Cruz, Jorge Gayoso, Codina, Jose Gomez, Gressin, Remy, Grigg, Andrew, Gurion, Ronit, Christensen, Jacob Haaber, Haioun, Corinne, Hajek, Roman, Hanel, Mathias, Hatake, Kiyohiko, Hensen, Robert, Horowitz, Netanel, Horwitz, Steven, Huttmann, Andreas, Illes, Arpad, Illidge, Tim, Ishizawa, Kenichi, Islas-Ohlmayer, Miguel, Jacobsen, Eric, Janakiram, Murali, Jurczak, Wojciech, Kaminski, Mark, Kato, Koji, Kim, Won Seog, Kirgner, Ilya, Iyer, Swaminathan, Kuo, Ching-Yuan, Lazaroiu, Mihaela Cornelia, Du, Katell Le, Lee, Jong-Seok, LeGouill, Steven, Lennard, Anne, LaRosee, Paul, Levi, Itai, Link, Brian, Maisonneuve, Herve, Maruyama, Dai, Mayer, Jiri, McCarty, John, McKay, Pam, Minami, Yosuke, Mocikova, Heidi, Morra, Enrica, Morschhauser, Franck, Munoz, Javier, Nagai, Hirokazu, O'Connor, Owen, Opat, Stephen, Pettengell, Ruth, Pezzutto, Antonio, Pfreundschuh, Michael, Pluta, Andrzej, Porcu, PierLuigi, Pro, Barbara, Quach, Hang, Rambaldi, Alessandro, Renwick, William, Reyes, Ruben, Izquierdo, Antonia Rodriguez, Rossi, Giuseppe, Ruan, Jia, Rusconi, Chiara, Salles, Gilles, Santoro, Armando, Sarriera, Jose, Savage, Kerry, Shibayama, Hirohiko, Shustov, Andrei, Suh, Cheolwon, Sureda, Anna, Tanimoto, Mitsune, Taniwaki, Masafumi, Tilly, Herve, Tobinai, Kensei, Trneny, Marek, Trumper, Lorenz, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Vitolo, Umberto, Walewski, Jan, Weidmann, Eckhart, Wilhelm, Martin, Witzens-Harig, Mathias, Yacoub, Abdulraheem, Yamamoto, Kazuhito, Yeh, Su-Peng, Yoon, Sung-Soo, Yuen, Sam, Yun, Hwan Jung, Zain, Jasmine, Zinzani, Pier Luigi·2019·The Lancet

Abstract

SUMMARY Background Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas (PTCL). Methods ECHELON-2 (ClinicalTrials.gov No. NCT01777152) is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults with previously-untreated CD30-positive PTCL (targeting 75% with systemic anaplastic large cell lymphoma [sALCL]) were randomised 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. All subjects received cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on Day 1 of each cycle intravenously (IV) and prednisone 100 mg daily on Days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1·8 mg/kg and placebo form of vincristine on Day 1 of each cycle IV (A+CHP arm) or vincristine 1·4 mg/m2 and placebo form of brentuximab vedotin IV (CHOP arm). Randomization was stratified by histological subtype as per local pathology assessment and by international prognostic index (IPI) score. The primary endpoint, progression-free survival (PFS) per blinded independent central review, was analysed by the intent-to-treat. Findings A total of 452 subjects were enrolled between January 24, 2013 and November 07, 2016 and 226 subjects were randomly assigned to each arm. The hazard ratios of both the PFS (0·71 [95% CI: 0·54, 0·93], p=0·0110) and overall survival (OS) (0·66 [95% confidence interval {CI}: 0·46, 0·95], p=0·0244) favoured A+CHP over CHOP. The median PFS was 48·2 months (95% CI: 35·2, not evaluable) versus 20·8 months (95% CI: 12·7, 47·6), for A+CHP and CHOP, respectively. The median was not met for OS. Adverse events (AEs), including incidence and severity of febrile neutropenia (in 41 subjects (18%) in A+CHP arm and 33 (15%) in CHOP) and peripheral neuropathy (in 117 subjects (52%) in A+CHP arm and 124 (55%) in CHOP), were similar between arms. Fatal AEs occurred in 7 subjects (3%) in the A+CHP arm and 9 subjects (4%) in the CHOP arm. Interpretation Frontline treatment with A+CHP is superior to CHOP for subjects with CD30-positive PTCL as demonstrated by a statistically significant improvement in PFS and OS with a manageable safety profile. Funding Supported by Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)32984-2

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 739

Metadata

Authors
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., Trümper, L., Aboulafia, D., Advani, R., Alpdogan, O., Ando, K., Arcaini, L., Baldini, L., Bellam, N., Bartlett, N., Belada, D., Yehuda, D. B., Benedetti, F., Borchman, P., Bordessoule, D., Brice, P., Briones, J., Caballero, D., Carella, A. M., Chang, H., Cheong, J. W., Cho, S.-G., Choi, I., Choquet, S., Colita, A., Congui, A. G., D'amore, F., Dang, N., Davison, K., de Guibert, S., Brown, P. D. N., Delwail, V., Demeter, J., di Raimondo, F., Do, Y. R., Domingo, E., Douvas, M., Dreyling, M., Ernst, T., Fanale, M., Fay, K., Feldman, T., Ferrero, S. F., Flinn, I. W., Forero-Torres, A., Fox, C., Friedberg, J., Fukuhara, N., Garcia-Marco, J., Cruz, J. G., Codina, J. G., Gressin, R., Grigg, A., Gurion, R., Christensen, J. H., Haioun, C., Hajek, R., Hanel, M., Hatake, K., Hensen, R., Horowitz, N., Horwitz, S., Huttmann, A., Illes, A., Illidge, T., Ishizawa, K., Islas-Ohlmayer, M., Jacobsen, E., Janakiram, M., Jurczak, W., Kaminski, M., Kato, K., Kim, W. S., Kirgner, I., Iyer, S., Kuo, C.-Y., Lazaroiu, M. C., Du, K. L., Lee, J.-S., LeGouill, S., Lennard, A., LaRosee, P., Levi, I., Link, B., Maisonneuve, H., Maruyama, D., Mayer, J., McCarty, J., McKay, P., Minami, Y., Mocikova, H., Morra, E., Morschhauser, F., Munoz, J., Nagai, H., O'Connor, O., Opat, S., Pettengell, R., Pezzutto, A., Pfreundschuh, M., Pluta, A., Porcu, P., Pro, B., Quach, H., Rambaldi, A., Renwick, W., Reyes, R., Izquierdo, A. R., Rossi, G., Ruan, J., Rusconi, C., Salles, G., Santoro, A., Sarriera, J., Savage, K., Shibayama, H., Shustov, A., Suh, C., Sureda, A., Tanimoto, M., Taniwaki, M., Tilly, H., Tobinai, K., Trneny, M., Trumper, L., Tsukamoto, N., Tsukasaki, K., Vitolo, U., Walewski, J., Weidmann, E., Wilhelm, M., Witzens-Harig, M., Yacoub, A., Yamamoto, K., Yeh, S.-P., Yoon, S.-S., Yuen, S., Yun, H. J., Zain, J., & Zinzani, P. L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-01
Volume
393
Issue
10168
Pages
229-240
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2903308035
Cited by
739
References
17
FWCI
49.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32984-2
The paper
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., . . . Zinzani, P. L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32984-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.